- Who We Are and What We Do
- Research Projects
- HIV Vaccine Trials Unit (HVTU)
- Penn Center for AIDS Research (CFAR)
- Risk Assessment Battery (RAB)
- Community Advisory Board
- Contact Us
- Support Our Work
- Follow Us on Twitter
Welcome to the HIV/AIDS Prevention Research Division
The mission of the HIV/AIDS Prevention Research Division is to develop and evaluate interventions designed to reduce the spread of HIV and other blood-borne infections among injection and non-injection drug users. The Division promotes the application of scientifically sound data in the development of public health policies designed to respond to the HIV epidemic among drug users.
In The News
David S. Metzger, PhD was quoted in a Philadelphia Inquirer article that reported on a spike in syphilis cases and sharp cuts in state funding to Philadelphia for HIV/AIDS, which are presenting a challenge to public-health workers tasked with preventing the spread of sexually transmitted diseases.
PRO 2000: A gel designed to prevent HIV infection in women
Lisa A. Maslankowski, MD was quoted in an article from The Philadelphia Bulletin, which notes that a gel designed to prevent HIV infection has proven promising, according to researchers at the University of Pennsylvania School of Medicine. The microbicide gel, PRO 2000, is a gel designed to prevent HIV infection in women and was found to be 30% effective, according to results from a clinical trial.
Lisa A. Maslankowski, MD, principal investigator of HPTN 035 and lead researcher of the HIV/AIDS Prevention Research Division's Microbicide Trials Unit at the University of Pennsylvania was quoted in a Penn Medicine News article, regarding results of a clinical trial which is the first human clinical study to suggest that a microbicide gel may prevent male-to-female sexual transmission of HIV infection.
David S. Metzger, PhD was quoted in a Philadelphia Inquirer article, regarding the high rate of new HIV cases in Philadelphia. The measures described in the article show that Philadelphians are being infected at a rate more than 50 percent higher than residents of New York City and five times the national average.
David S. Metzger, PhD, director of the HIV/AIDS Prevention Research Division and research associate professor of Psychiatry, was quoted in an article published by JAMA, regarding integrated care models for patients who are infected with HIV and also have simultaneous substance abuse problems and mental illness. Dr. Metzer reported that treating substance abuse offers a collateral benefit of reducing HIV transmission.